Relationship between piperacillin concentrations, clinical factors and piperacillin/tazobactam-associated acute kidney injury.

Sonya C Tang GirdwoodDenise HassonJ Timothy CaldwellCara SlagleShun DongLin FeiPeter TangAlexander A VinksJennifer KaplanStuart L Goldstein

Published in: The Journal of antimicrobial chemotherapy (2022)

We show a relationship between estimated piperacillin AUC and highest Cmin in the first 24 hours of piperacillin/tazobactam therapy and piperacillin-associated AKI, suggesting total piperacillin exposure early in the course is associated with AKI development. These data could serve as the foundation for implementation of model-informed precision dosing to reduce AKI incidence in patients given piperacillin/tazobactam.

Keyphrases

acute kidney injury
cardiac surgery
end stage renal disease
primary care
newly diagnosed
healthcare
ejection fraction
chronic kidney disease
peritoneal dialysis
stem cells
machine learning
mesenchymal stem cells
quality improvement
data analysis
patient reported
chemotherapy induced